|
|
News Breaks
|
October 19, 2009
|
| 08:35 EDT |  | ENDP |
| theflyonthewall.com: | Endo Pharmaceuticals receives complete response letter from FDA | | Endo Pharmaceuticals announced that it received a Complete Response letter from the FDA regarding the New Drug Application for FORTESTA 2% Gel for men diagnosed with low testosterone, also known as hypogonadism. "The potential of this action was considered in the structure of the deal to in-license this product," said Dr. Ivan Gergel, M.D., executive vice president, R&D, Endo Pharmaceuticals. "We will continue to work closely with the FDA to address their questions and we expect to file a complete response, mid-2010. Endo is committed to bringing FORTESTA to market to offer men another option for testosterone replacement therapy." :theflyonthewall.com |
|
|
News For ENDP From The Last 14 Days Check below for free stories on ENDP the last two weeks.
There are 3 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 13, 2012
|
| 07:30 EDT |  | ENDP |
|
|
February 7, 2012
|
| 06:30 EDT | | ENDP |
|
|
January 31, 2012
|
| 11:21 EDT |  | ENDP |
|
|
|
|
|
Subscribe for More Information